+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients



Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients



Cancer Research 58(3): 500-503



The synovial fluid or group II secretory phospholipase A2 (sPLA2) has been implicated in various inflammatory processes and has been shown to release arachidonic acid for prostaglandin biosynthesis. In human colorectal cancer, both arachidonic acid and eicosanoid levels are elevated. Recently, sPLA2 has been identified as a candidate gene that modifies the Apc gene in the Min mouse, a murine model for familial adenomatous polyposis (FAP). Loss of sPLA2 gene function results in susceptibility to the Min phenotype and the formation of multiple intestinal polyps, whereas mice expressing an active sPLA2 gene are resistant to polyp formation. Therefore, there are two potentially contrasting roles for sPLA2 in colon cancer; one is protection against polyp formation, and the other, the release of arachidonic acid for prostaglandin production and subsequent tumor promotion. To investigate these contrasting dual roles of sPLA2, we have examined the expression and sequence of the sPLA2 mRNA in normal mucosa and duodenal and colorectal polyps from FAP patients. In 11 of 14 patients, there was a significant increase in sPLA2 mRNA levels in the adenoma over the normal tissue. In some cases, there was over 100-fold increase in mRNA levels in the adenoma compared with normal tissue. Analysis of multiple adenomatous polyps from individual patients revealed that not all polyps contained elevated levels of sPLA2 mRNA. Immunoblot analysis also showed that sPLA2 protein expression was elevated in adenoma over normal tissue in five of six FAP patients analyzed. Furthermore, sequence analysis of sPLA2 mRNA present in these samples did not reveal mutations in the coding region. The implications of the up-regulation of sPLA2 in FAP is not clear, but unlike the Min mouse model, it does not seem to have a significant effect on polyp formation. In contrast, the high level of sPLA2 expression is more likely contributing to the elevated levels of arachidonic acid found in colorectal cancer and, in conjunction with the elevated expression of cyclooxygenase-2, could be another factor in tumor formation.

(PDF emailed within 1 workday: $29.90)

Accession: 009145342

Download citation: RISBibTeXText

PMID: 9458096


Related references

p53 Protein overexpression in colorectal tumors from patients with familial adenomatous polyposis: is it an early or late event?. American Journal of Gastroenterology 91(1): 11-14, 1996

Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis. Pathology International 52(4): 272-276, April, 2002

Overexpression of Wnt target genes in adenomas of familial adenomatous polyposis patients. Anticancer Research 22(6a): 3409-3414, 2003

K-ras gene mutation in colorectal adenomas and carcinomas from familial adenomatous polyposis patients. Surgical Oncology 1(4): 269-274, 1992

Clonality of dysplastic epithelium in colorectal adenomas from familial adenomatous polyposis patients. Cancer Research 57(3): 355-361, 1997

Unequal expression of APC alleles in colorectal adenomas of patients with familial adenomatous polyposis. Gastroenterology 108(4 SUPPL ): A540, 1995

Application of serum protein markers to distinguish familial adenomatous polyposis (FAP) and sporadic colorectal adenomas. Zhonghua Zhong Liu Za Zhi 31(3): 192-195, 2010

Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Research 52(14): 3965-3971, 1992

Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Research 52(13): 3801-3803, 1992

Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or "multiple" colorectal adenomas. Proceedings of the National Academy of Sciences of the United States of America 99(5): 2954-2958, 2002

Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis. Zhonghua Yi Xue Za Zhi 86(8): 526-529, 2006

Mutation analysis of the adenomatous polyposis coli (APC) gene in northwest Spanish patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer. Human Mutation 18(4): 355-355, 2001

Multiple colorectal adenomas, familial adenomatous polyposis and germline mutations in myh. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 361, 2003

Undifferentiated columnar cells in colorectal adenomas and familial adenomatous polyposis. Journal of Pathology 158(2): 93-96, 1989